Physician profile
Michael Parslow
NPI 1437569746
$2,126.98
in general payments reported to CMS, 2019-2025
28 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $214 · 2023: $275 · 2024: $465 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $325.34 | 2019-2025 | |
| Novo Nordisk INC | $287.12 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $209.99 | 2019-2025 | Breztri, Farxiga |
| Amgen INC. | $159.74 | 2019-2020 | |
| Glaxosmithkline, LLC. | $158.48 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Madrigal Pharmaceuticals | $114.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.73 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $100.86 | 2023-2024 | |
| Lilly USA, LLC | $73.74 | 2019-2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $73.60 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $63.64 | 2023-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $54.50 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.43 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $46.18 | 2024-2025 | Rexulti |
| Lundbeck LLC | $39.29 | 2024 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29.18 | 2024-2025 | |
| Dexcom, INC. | $26.79 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $26.22 | 2024 | Gemtesa |
| Daiichi Sankyo INC. | $24.61 | 2024 | Injectafer |
| Xeris Pharmaceuticals, INC. | $23.18 | 2025 | Keveyis |
| Astellas Pharma US INC | $22.06 | 2019 | |
| Gilead Sciences, INC. | $21.84 | 2024 | |
| Phathom Pharmaceuticals, INC. | $18.90 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $18.56 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.88 | 2023 | Trulance, Xifaxan |
| Allergan, INC. | $14.40 | 2019 | |
| Axsome Therapeutics, INC. | $13.51 | 2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Parslow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.